Session Chair Profile
MBA, CEO, Omicia
Matt Tindall has more than two decades of healthcare experience spanning general management, corporate development, strategy consulting, digital marketing and commercial operations. Prior to Omicia, he served as the general manager of the Consumer Solutions division of IMS Health, a leading global information and technology services company in the healthcare industry. Matt was VP Marketing at Digitas Health New York, worked in strategic business development for Celera Genomics, led a cardiovascular business development team focused on the development of novel gene therapy, cell therapy and biomaterial products at Genzyme Corporation and co-founded and managed the start-up biopharmaceutical company Sarentis Therapeutics. Matt received his B.S. in Human Physiology from Lyman Brigg’s College at Michigan State University and his M.B.A. from the University of Texas at Austin.
Scaling Clinical NGS: From Panels to Exomes to WGS
Advances in NGS technologies coupled with decreased cost are opening the doors to broad genomic applications in the clinic. Thus, Clinical NGS testing is expanding from panels to exomes to whole genomes. Interpretation and reporting capabilities in conjunction with advanced computational algorithms are required to successfully maximize diagnostic outcome.
Session Abstract – PMWC 2017 Silicon Valley
Session Synopsis: The clinical NGS workflow is complex in nature, spanning sequence data generation, data management, data analysis and interpretation, as well as reporting of the actionable findings. Building the right solution requires a good understanding of the processes to be supported and the needs to be addressed for individual constituents. In this session we will hear about some of the solutions that are available today as well as the perspective of a genetic counselor, an important stakeholder who adds value toward the end of this workflow.